Soligenix Inc. announced the results of its compatibility study evaluating HyBryte (synthetic hypericin) for the treatment of cutaneous T-cell lymphoma have been published in the Journal of the European Academy of Dermatology & Venereology Clinical Practice.
Alligator Bioscience has announced the initiation of a phase I clinical study (NCT06205849) to evaluate the safety and efficacy of mitazalimab (CD40 mAb agonist) injected intratumorally at the time of surgical irreversible electroporation (IRE) in patients with locally advanced pancreatic cancer.
Kyowa Kirin published a patient-focused global consensus statement that highlights 12 recommendations for healthcare authorities, policymakers, hospitals, and clinicians to drive positive change for the global cutaneous T-cell lymphoma patient community.
Merck announced the discontinuation of the vibostolimab and pembrolizumab coformulation arm of the phase III KeyVibe-010 trial.
FDA and the European Medicines Agency granted an Orphan Drug Designation to Carthera for the use of carboplatin when used with SonoCloud technology in the treatment with malignant glioma.
Leal Health announced a first-of-its-kind GenAI single point of access technology designed to allow healthcare providers, caregivers, and cancer patients to understand diagnostics and identify personalized treatment options to support the treatment decision process.
Tumor heterogeneity is a well-recognized hurdle to successful cancer therapy, often leading to resistance and treatment failure.
If the FDA Oncology Center of Excellence (OCE) began an “innovation challenge” in oncology drug development, what would that look like?
“How often do you receive financial support from parents or other relatives?”
Norman Wolmark, chairman of the NSABP Foundation Inc., and group chair and contact principal investigator of NRG Oncology, received the 2024 American Surgical Association Medallion for Advancement of Surgical Care at the American Surgical Association’s 144th annual meeting in Washington, DC.
